Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 induction dose study of ABP-700 in healthy adults
NL-OMON43769Phase 1Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of moxetomidate in Not applicable (3 arms), sponsored by The Medicines Company. Primary endpoint: Safety and tolerability. Started Nov 2015; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON43769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43769.